Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
China · Delayed Price · Currency is CNY 19.90
+0.03 (0.15%)
May 29, 2026, 3:00 PM CST
SHA:600645 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 110.05 | 113.83 | 100.35 | 106.45 | 112.99 | 155.32 |
Depreciation & Amortization | 130.69 | 130.69 | 141.97 | 143.6 | 138.21 | 124.62 |
Other Amortization | 34.27 | 34.27 | 28.1 | 29.02 | 26.12 | 23.09 |
Loss (Gain) From Sale of Assets | -6.41 | -6.41 | -1.3 | -3.67 | -2.03 | -1.49 |
Asset Writedown & Restructuring Costs | 1.34 | 1.34 | 4.68 | 0.31 | 0.8 | 27.64 |
Loss (Gain) From Sale of Investments | 7.92 | 7.92 | 44.33 | 47.94 | 8.71 | -85.87 |
Provision & Write-off of Bad Debts | 21.93 | 21.93 | 27.68 | 20.9 | 17.63 | 38.21 |
Other Operating Activities | -13.57 | 0.9 | 3.12 | 2.09 | -2.04 | -5.18 |
Change in Accounts Receivable | -20.2 | -20.2 | -31.23 | -12.23 | -31.93 | 30.73 |
Change in Inventory | -7.36 | -7.36 | -0.63 | -9.25 | -27.64 | -4.56 |
Change in Accounts Payable | -3.37 | -3.37 | -11.18 | -1.07 | 35.06 | 19.42 |
Change in Other Net Operating Assets | - | - | -0.03 | 12.21 | -6.68 | -19.46 |
Operating Cash Flow | 295.38 | 313.63 | 285.19 | 299.02 | 261.89 | 320.96 |
Operating Cash Flow Growth | -4.77% | 9.97% | -4.62% | 14.18% | -18.40% | 31.35% |
Capital Expenditures | -46.84 | -49.56 | -67.32 | -88.61 | -99.19 | -127.74 |
Sale of Property, Plant & Equipment | 0.33 | 0.31 | 0.78 | 0.19 | 1.42 | 12.63 |
Investment in Securities | -145.34 | -710.33 | 1.95 | -2.06 | -0.57 | -18.95 |
Other Investing Activities | 14.3 | 11.74 | 0.72 | - | - | - |
Investing Cash Flow | -177.56 | -747.85 | -63.86 | -90.49 | -98.34 | -134.05 |
Long-Term Debt Repaid | - | -65.04 | -41.19 | -35.76 | -41.33 | -29.13 |
Net Debt Issued (Repaid) | -65.04 | -65.04 | -41.19 | -35.76 | -41.33 | -29.13 |
Repurchase of Common Stock | - | - | -200.03 | - | - | - |
Common Dividends Paid | - | - | - | - | - | -1.61 |
Other Financing Activities | -6.91 | -9.07 | -43.69 | 17.03 | 33.58 | -18.97 |
Financing Cash Flow | -71.95 | -74.1 | -284.91 | -18.73 | -7.75 | -49.71 |
Foreign Exchange Rate Adjustments | -13.04 | -9.25 | 7.3 | 10.22 | 35.3 | -7.44 |
Net Cash Flow | 32.83 | -517.56 | -56.28 | 200.02 | 191.1 | 129.75 |
Free Cash Flow | 248.55 | 264.07 | 217.87 | 210.4 | 162.7 | 193.22 |
Free Cash Flow Growth | -1.54% | 21.21% | 3.55% | 29.32% | -15.79% | 26.59% |
Free Cash Flow Margin | 17.48% | 18.15% | 13.74% | 13.23% | 10.46% | 12.58% |
Free Cash Flow Per Share | 0.54 | 0.58 | 0.48 | 0.46 | 0.35 | 0.41 |
Cash Interest Paid | - | - | 0.59 | 0.92 | 1.27 | - |
Cash Income Tax Paid | 164.51 | 159.44 | 162.15 | 170.94 | 110.96 | 116.78 |
Levered Free Cash Flow | 187.34 | 195.78 | 191.89 | 164.65 | 141.27 | 197.98 |
Unlevered Free Cash Flow | 189.36 | 197.8 | 195.03 | 167.79 | 143.78 | 199.95 |
Change in Working Capital | 9.17 | 9.17 | -63.75 | -47.63 | -38.49 | 44.62 |